{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:52:19Z","timestamp":1791341539503,"version":"4.3.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T00:00:00Z","timestamp":1509408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T00:00:00Z","timestamp":1509408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The zebrafish has become a popular human tumour xenograft model, particularly for solid tumours including prostate cancer (PCa). To date PCa xenotransplantation studies in zebrafish have not been performed in the presence of testosterone, even when employing androgen-dependent cell models, such as the LNCaP cell line. Thus, with the goal of more faithfully modelling the hormonal milieu in which PCa develops in humans, we sought to determine the effects of exogenous testosterone on the growth of LNCaP, or androgen-independent C4-2 cells xenografted into zebrafish embryos. Testosterone significantly increased engrafted LNCaP proliferation compared to control xenografts, which could be inhibited by co-administration of the anti-androgen\u00a0receptor drug, enzalutamide. By contrast, C4-2 cell growth was not affected by either testosterone or enzalutamide. Enzalutamide also induced bradycardia and death in zebrafish embryos in a dose-dependent manner and strongly synergized with the potassium-channel blocking agent, terfenadine, known to induce long QT syndrome and cardiac arrhythmia. Together, these data not only indicate that testosterone administration should be considered in all PCa xenograft studies in zebrafish but also highlights the unique opportunity of this preclinical platform to simultaneously evaluate efficacy and toxicity of novel therapies and\/or protective agents towards developing safer and more effective PCa treatments.<\/jats:p>","DOI":"10.1038\/s41598-017-14413-w","type":"journal-article","created":{"date-parts":[[2017,10,25]],"date-time":"2017-10-25T14:08:35Z","timestamp":1508940515000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Enzalutamide inhibits testosterone-induced growth of human prostate cancer xenografts in zebrafish and can induce bradycardia"],"prefix":"10.1038","volume":"7","author":[{"given":"Nicole","family":"Melong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelby","family":"Steele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Holly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin C.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Zoubeidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason N.","family":"Berman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3466-6316","authenticated-orcid":false,"given":"Graham","family":"Dellaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,31]]},"reference":[{"key":"14413_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1464-410X.2012.11215.x","volume":"109","author":"F Schroder","year":"2012","unstructured":"Schroder, F., Crawford, E. D., Axcrona, K., Payne, H. & Keane, T. E. Androgen deprivation therapy: past, present and future. BJU Int. \n                           109, 1\u201312 (2012).","journal-title":"BJU Int."},{"key":"14413_CR2","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","volume":"65","author":"A Heidenreich","year":"2014","unstructured":"Heidenreich, A. et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol. \n                           65, 467\u2013479 (2014).","journal-title":"Eur. Urol."},{"key":"14413_CR3","first-page":"1","volume":"14","author":"H Lepor","year":"2012","unstructured":"Lepor, H. & Shore, N. D. LHRH Agonists for the Treatment of Prostate Cancer: 2012. Rev. Urol. \n                           14, 1\u201312 (2012).","journal-title":"Rev. Urol."},{"key":"14413_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.critrevonc.2016.07.005","volume":"106","author":"G Baciarello","year":"2016","unstructured":"Baciarello, G. & Sternberg, C. N. Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide. Crit. Rev. Oncol. Hematol. \n                           106, 14\u201324 (2016).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"14413_CR5","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.urolonc.2014.11.006","volume":"33","author":"FG Rick","year":"2015","unstructured":"Rick, F. G. & Schally, A. V. Bench-to-bedside development of agonists and antagonists of luteinizing hormone-releasing hormone for treatment of advanced prostate cancer. Urol. Oncol. Semin. Orig. Investig. \n                           33, 270\u2013274 (2015).","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"14413_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1517\/14656566.2014.852184","volume":"15","author":"RR Deshmukh","year":"2014","unstructured":"Deshmukh, R. R., Schmitt, S. M., Hwang, C. & Dou, Q. P. Chemotherapeutic inhibitors in the treatment of prostate cancer. Expert Opin. Pharmacother. \n                           15, 11\u201322 (2014).","journal-title":"Expert Opin. Pharmacother."},{"key":"14413_CR7","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/path.4272","volume":"232","author":"DN Rodrigues","year":"2014","unstructured":"Rodrigues, D. N., Butler, L. M., Estelles, D. L. & De Bono, J. S. Molecular pathology and prostate cancer therapeutics: From biology to bedside. J. Pathol. \n                           232, 178\u2013184 (2014).","journal-title":"J. Pathol."},{"key":"14413_CR8","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1242\/dmm.015784","volume":"7","author":"CJ Veinotte","year":"2014","unstructured":"Veinotte, C. J., Dellaire, G. & Berman, J. N. Hooking the big one: the potential of zebrafish xenotransplantation to reform cancer drug screening in the genomic era. Dis. Model. Mech. \n                           7, 745\u2013754 (2014).","journal-title":"Dis. Model. Mech."},{"key":"14413_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3324\/haematol.2014.110742","volume":"100","author":"V Bentley","year":"2015","unstructured":"Bentley, V. et al. Focused chemical genomics using zebrafish xenotransplantation as a pre-clinical therapeutic platform for T-cell acute lymphoblastic leukemia. Haematologica \n                           100, 70\u201376 (2015).","journal-title":"Haematologica"},{"key":"14413_CR10","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/j.1365-2141.2011.08661.x","volume":"153","author":"DP Corkery","year":"2011","unstructured":"Corkery, D. P., Dellaire, G. & Berman, J. N. Leukaemia xenotransplantation in zebrafish \u2013 chemotherapy response assay in vivo. Br. J. Haematol. \n                           153, 786\u2013789 (2011).","journal-title":"Br. J. Haematol."},{"key":"14413_CR11","doi-asserted-by":"publisher","first-page":"5995","DOI":"10.1016\/j.bmc.2013.07.042","volume":"21","author":"CLA Hawco","year":"2013","unstructured":"Hawco, C. L. A. et al. Synthesis and biological evaluation of prodigiosene conjugates of porphyrin, estrone and 4-hydroxytamoxifen. Bioorganic Med. Chem. \n                           21, 5995\u20136002 (2013).","journal-title":"Bioorganic Med. Chem."},{"key":"14413_CR12","doi-asserted-by":"crossref","unstructured":"Ghotra, V. P. S. et al. Automated whole animal bio-imaging assay for human cancer dissemination. PLoS One \n                           7 (2012).","DOI":"10.1371\/journal.pone.0031281"},{"key":"14413_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-453","volume":"13","author":"Y Teng","year":"2013","unstructured":"Teng, Y. et al. Evaluating human cancer cell metastasis in zebrafish. BMC Cancer \n                           13, 453 (2013).","journal-title":"BMC Cancer"},{"key":"14413_CR14","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1158\/0008-5472.CAN-14-0629","volume":"75","author":"VPS Ghotra","year":"2015","unstructured":"Ghotra, V. P. S. et al. SYK is a candidate kinase target for the treatment of advanced prostate cancer. Cancer Res. \n                           75, 230\u2013240 (2015).","journal-title":"Cancer Res."},{"key":"14413_CR15","doi-asserted-by":"publisher","first-page":"266ra170","DOI":"10.1126\/scitranslmed.3010189","volume":"6","author":"Y Liu","year":"2014","unstructured":"Liu, Y. et al. Visnagin protects against doxorubicin-induced cardiomyopathy through inhibtion of mitochondrial malate dehydrogenase. Sci. Transl. Med. \n                           6, 266ra170 (2014).","journal-title":"Sci. Transl. Med."},{"key":"14413_CR16","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/ijc.2910570319","volume":"57","author":"H-C Wu","year":"1994","unstructured":"Wu, H.-C. et al. Derivation of androgen-independent LNCaP prostatic cancer cell sublines: Role of bone stromal cells. Int. J. Cancer \n                           57, 406\u2013412 (1994).","journal-title":"Int. J. Cancer"},{"key":"14413_CR17","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/pros.22910","volume":"75","author":"JD Murga","year":"2015","unstructured":"Murga, J. D. et al. Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer. Prostate \n                           75, 242\u2013254 (2015).","journal-title":"Prostate"},{"key":"14413_CR18","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1002\/jat.2755","volume":"32","author":"D Wen","year":"2012","unstructured":"Wen, D., Liu, A., Chen, F., Yang, J. & Dai, R. Validation of visualized transgenic zebrafish as a high throughput model to assay bradycardia related cardio toxicity risk candidates. J. Appl. Toxicol. \n                           32, 834\u2013842 (2012).","journal-title":"J. Appl. Toxicol."},{"key":"14413_CR19","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1161\/01.CIR.94.4.817","volume":"94","author":"M Roy","year":"1996","unstructured":"Roy, M., Dumaine, R. & Brown, A. M. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation \n                           94, 817\u2013823 (1996).","journal-title":"Circulation"},{"key":"14413_CR20","first-page":"1","volume":"2115","author":"M Sun","year":"2015","unstructured":"Sun, M. et al. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy. JAMA Oncol. \n                           2115, 1\u20138 (2015).","journal-title":"JAMA Oncol."},{"key":"14413_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11934-016-0584-4","volume":"17","author":"JL Silberstein","year":"2016","unstructured":"Silberstein, J. L., Taylor, M. N. & Antonarakis, E. S. Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer. Curr. Urol. Rep. \n                           17, 1\u201310 (2016).","journal-title":"Curr. Urol. Rep."},{"key":"14413_CR22","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1002\/cncr.22933","volume":"110","author":"CS Saigal","year":"2007","unstructured":"Saigal, C. S. et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer \n                           110, 1493\u20131500 (2007).","journal-title":"Cancer"},{"key":"14413_CR23","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","volume":"24","author":"NL Keating","year":"2006","unstructured":"Keating, N. L., O\u2019Malley, A. J. & Smith, M. R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J. Clin. Oncol. \n                           24, 4448\u20134456 (2006).","journal-title":"J. Clin. Oncol."},{"key":"14413_CR24","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1200\/JCO.2006.09.3369","volume":"25","author":"AV D\u2019Amico","year":"2007","unstructured":"D\u2019Amico, A. V. et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J. Clin. Oncol. \n                           25, 2420\u20132425 (2007).","journal-title":"J. Clin. Oncol."},{"key":"14413_CR25","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1093\/jnci\/djm168","volume":"99","author":"HK Tsai","year":"2007","unstructured":"Tsai, H. K., D\u2019Amico, A. V., Sadetsky, N., Chen, M.-H. & Carroll, P. R. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J. Natl. Cancer Inst. \n                           99, 1516\u20131524 (2007).","journal-title":"J. Natl. Cancer Inst."},{"key":"14413_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.eururo.2010.07.013","volume":"58","author":"JA Smith","year":"2010","unstructured":"Smith, J. A. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: A science advisory from the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology. Eur. Urol. \n                           58, 629 (2010).","journal-title":"Eur. Urol."},{"key":"14413_CR27","doi-asserted-by":"publisher","first-page":"4578","DOI":"10.1200\/jco.2004.22.14_suppl.4578","volume":"22","author":"M Garnick","year":"2004","unstructured":"Garnick, M., Pratt, C., Campion, M. & Shipley, J. The effect of hormonal therapy for prostate cancer on the electrocardiographic QT interval: phase 3 results following treatment with leuprolide and goserelin, alone or with bicalutamide, and the GnRH antagonist abarelix. J. Clin. Oncolology \n                           22, 4578 (2004).","journal-title":"J. Clin. Oncolology"},{"key":"14413_CR28","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3109\/21681805.2013.860189","volume":"48","author":"FB Thomsen","year":"2013","unstructured":"Thomsen, F. B. et al. Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate. Scand. J. Urol. \n                           48, 268\u2013275 (2013).","journal-title":"Scand. J. Urol."},{"key":"14413_CR29","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1002\/1097-0142(19931215)72:12+<3888::AID-CNCR2820721726>3.0.CO;2-B","volume":"72","author":"L Denis","year":"1993","unstructured":"Denis, L. & Murphy, G. P. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer \n                           72, 3888\u201395 (1993).","journal-title":"Cancer"},{"key":"14413_CR30","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/pros.22753","volume":"74","author":"KJ Pienta","year":"2014","unstructured":"Pienta, K. J., Walia, G., Simons, J. W. & Soule, H. R. Beyond the androgen receptor: New approaches to treating metastatic prostate cancer. Report of the 2013 Prouts Neck Prostate Cancer Meeting. Prostate \n                           74, 314\u2013320 (2014).","journal-title":"Prostate"},{"key":"14413_CR31","first-page":"27","volume":"13","author":"A Pozniak","year":"2008","unstructured":"Pozniak, A. New drugs: Enzalutamide. J HIV Ther \n                           13, 27\u201333 (2008).","journal-title":"J HIV Ther"},{"issue":"8","key":"14413_CR32","first-page":"1584","volume":"57","author":"N Sato","year":"1997","unstructured":"Sato, N. et al. A metastatic and androgen-sensitive human prostate cancer model usingintraprostatic inoculation of LNCaP cells in SCID mice. Cancer Res. \n                           57(8), 1584\u20139 (1997).","journal-title":"Cancer Res."},{"key":"14413_CR33","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/pros.22740","volume":"74","author":"N Bansal","year":"2014","unstructured":"Bansal, N. et al. Enrichment of human prostate cancer cells with tumor initiating properties in mouse and zebrafish xenografts by differential adhesion. Prostate \n                           74, 187\u2013200 (2014).","journal-title":"Prostate"},{"key":"14413_CR34","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nm972","volume":"10","author":"CD Chen","year":"2004","unstructured":"Chen, C. D. et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. \n                           10, 33\u201339 (2004).","journal-title":"Nat. Med."},{"key":"14413_CR35","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/S0008-6363(01)00429-1","volume":"53","author":"TV Pham","year":"2002","unstructured":"Pham, T. V. & Rosen, M. R. Sex, hormones, and repolarization. Cardiovasc. Res. \n                           53, 740\u2013751 (2002).","journal-title":"Cardiovasc. Res."},{"key":"14413_CR36","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1089\/jwh.2011.3444","volume":"21","author":"T Sedlak","year":"2012","unstructured":"Sedlak, T., Shufelt, C., Iribarren, C. & Merz, C. N. B. Sex hormones and the QT interval: a review. J. Womens. Health (Larchmt). \n                           21, 933\u201341 (2012).","journal-title":"J. Womens. Health (Larchmt)."},{"key":"14413_CR37","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.amjcard.2008.11.041","volume":"103","author":"B Charbit","year":"2009","unstructured":"Charbit, B. et al. Effects of Testosterone on Ventricular Repolarization in Hypogonadic Men. Am. J. Cardiol. \n                           103, 887\u2013890 (2009).","journal-title":"Am. J. Cardiol."},{"key":"14413_CR38","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/aje\/kwr172","volume":"174","author":"Y Zhang","year":"2011","unstructured":"Zhang, Y. et al. Sex-steroid hormones and electrocardiographic qt-interval duration: Findings from the third national health and nutrition examination survey and the multi-ethnic study of atherosclerosis. Am. J. Epidemiol. \n                           174, 403\u2013411 (2011).","journal-title":"Am. J. Epidemiol."},{"key":"14413_CR39","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1016\/j.hrthm.2014.06.023","volume":"11","author":"KE Odening","year":"2015","unstructured":"Odening, K. E., Koren, G., Hospital, R. I. & Medical, A. How do sex hormones modifiy arrhythmogeneis in long-QT syndrome? Sex hormone effects on arrhythmogenic substrate and triggered activity. Heart Rhythm \n                           11, 2107\u20132115 (2015).","journal-title":"Heart Rhythm"},{"key":"14413_CR40","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1747-5341-4-2","volume":"4","author":"N Shanks","year":"2009","unstructured":"Shanks, N., Greek, R. & Greek, J. Are animal models predictive for humans? Philos Ethics Humanit Med. \n                           4, 2 (2009).","journal-title":"Philos Ethics Humanit Med."},{"key":"14413_CR41","first-page":"153","volume":"7","author":"R Greasley","year":"2015","unstructured":"Greasley, R., Khabazhaitajer, M. & Rosario, D. J. A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer. Cancer Manag Res. \n                           7, 153\u201364 (2015).","journal-title":"Cancer Manag Res."},{"issue":"13","key":"14413_CR42","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1158\/1078-0432.CCR-05-0525","volume":"11","author":"MA Titus","year":"2005","unstructured":"Titus, M. A., Schell, M. J., Lih, F. B., Tomer, K. B. & Mohler, J. L. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res. \n                           11(13), 4653\u20137 (2005).","journal-title":"Clin Cancer Res."},{"key":"14413_CR43","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.stem.2007.11.002","volume":"2","author":"RM White","year":"2008","unstructured":"White, R. M. et al. Transparent adult zebrafish as a tool for in vivo transplantation analysis. Cell Stem Cell \n                           2, 183\u2013189 (2008).","journal-title":"Cell Stem Cell"},{"key":"14413_CR44","unstructured":"Westerfield, M. THE Zebrafish Book a Guide for the Laboratory Use of Zebrafish Danio* (Brachydanio) Rerio, 5th Edition (2007) (University of Oregon Press, 2000)."},{"key":"14413_CR45","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s10456-006-9040-2","volume":"9","author":"M Haldi","year":"2006","unstructured":"Haldi, M., Ton, C., Seng, W. L. & McGrath, P. Human melanoma cells transplanted into zebrafish proliferate, migrate, produce melanin, form masses and stimulate angiogenesis in zebrafish. Angiogenesis \n                           9, 139\u201351 (2006).","journal-title":"Angiogenesis"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-14413-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-14413-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-14413-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T12:48:59Z","timestamp":1671799739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-14413-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,31]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["14413"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-14413-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,31]]},"assertion":[{"value":"26 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"14698"}}